Rafael Aparecido Carvalho Souza

Dr. Rafael Aparecido Carvalho Souza

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LFLaísa de Paula Fernandes
Laísa de Paula Fernandes
JSJúlia M. B. Silva
Júlia M. B. Silva
DMDaniel Oliveira Silva Martins
Daniel Oliveira Silva Martins
MSMariana Brentini Santiago
Mariana Brentini Santiago
CMCarlos Henrique Martins
Carlos Henrique Martins
Carolina OliveiraCarolina Oliveira
Carolina Oliveira
Considering our previous findings on the remarkable activity exhibited by cobalt(III) with 2-acetylpyridine-N(4)-R-thiosemicarbazone (Hatc-R) compounds against Mycobacterium tuberculosis, the present study aimed to explored new structure features of the complexes of the type [Co(atc--R)2]Cl, where R = methyl (Me, 1) or phenyl (Ph, 2) (13C NMR, high-resolution mass spectrometry, LC–MS/MS, fragmentation study) together with its antibacterial and antiviral biological activities. The minimal inhibitory and minimal bactericidal concentrations (MIC and MBC) were determined, as well as the antiviral potential of the complexes on chikungunya virus (CHIKV) infection in vitro and cell viability. [Co(atc-Ph)2]Cl revealed promising MIC and MBC values which ranged from 0.39 to 0.78 µg/mL in two strains tested and presented high potential against CHIKV by reducing viral replication by up to 80%. The results showed that the biological activity is strongly influenced by the peripheral substituent groups at the N(4) position of the atc-R1− ligands. In addition, molecular docking analysis was performed. The relative binding energy of the docked compound with five bacteria strains was found in the range of −3.45 and −9.55 kcal/mol. Thus, this work highlights the good potential of cobalt(III) complexes and provide support for future studies on this molecule aiming at its antibacterial and antiviral therapeutic application.

1 June 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
AMAngélica Faleiros da Silva Maia
Angélica Faleiros da Silva Maia
RSRaoni Pais Siqueira
Raoni Pais Siqueira
FOFabrício Marques de Oliveira
Fabrício Marques de Oliveira
JFJoana Gasperazzo Ferreira
Joana Gasperazzo Ferreira
SSSilma Francielle da Silva
Silma Francielle da Silva
RTRobson Ricardo Teixeira
Robson Ricardo Teixeira

7 March 2024 in Journal of Cleaner Production
Verified
Journal Article
Closed access
Lucas Leão NascimentoLucas Leão Nascimento
Lucas Leão Nascimento
RSRafael Aparecido Carvalho Souza
Rafael Aparecido Carvalho Souza
JMJuliane Zacour Marinho
Juliane Zacour Marinho
Chuanyi WangChuanyi Wang
Chuanyi Wang
APAntonio Otavio Patrocinio
Antonio Otavio Patrocinio

1 February 2017 in Journal of Molecular Structure
Verified
Journal Article
Closed access
LFLucius F.O. Bomfim Filho
Lucius F.O. Bomfim Filho
MOMarcelo R.L. Oliveira
Marcelo R.L. Oliveira
LMLiany D.L. Miranda
Liany D.L. Miranda
AVAntonio E.C. Vidigal
Antonio E.C. Vidigal
SGSilvana Guilardi
Silvana Guilardi
MRMayura M.M. Rubinger
Mayura M.M. Rubinger

18 December 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RMRaiane Aparecida dos Santos Machado
Raiane Aparecida dos Santos Machado
RSRaoni Pais Siqueira
Raoni Pais Siqueira
FSFernanda Cardoso da Silva
Fernanda Cardoso da Silva
AMAndré Carlos Pereira Matos
André Carlos Pereira Matos
DBDayanne Silva Borges
Dayanne Silva Borges
TAThaise Gonçalves Araújo
Thaise Gonçalves Araújo
Background/Objectives: Triple-negative breast cancer (TNBC) is the most challenging molecular subtype of breast cancer (BC) in clinical practice, associated with a worse prognosis due to limited treatment strategies and its insensitivity to conventional drugs. Zinc is an important trace element for homeostasis, and its Schiff base metal complexes have shown promise in treating advanced tumors. In this study, four new heteroleptic Zn(II) complexes (1–4) with Schiff bases were synthesized, characterized, and evaluated for their activity in BC cells. Methods: Compounds were synthesized, characterized, and their crystal structures were determined. Biological activity was assessed using MTT, clonogenic, scratch wound healing, caspase 3 and 8 activity, qPCR, and chemosensitization assays. Results: The complexes exhibited cytotoxicity against MCF-7 (luminal BC), MDA-MB-453 (HER2-positive BC), and MDA-MB-231 (TNBC) cell lines, with IC50 values ranging from 0.01 to 20 µM. Complex 4 showed reduced cytotoxicity toward non-tumor cell lines. This, complexation with Zn(II) increased the cytotoxicity of the ligands, a trend not observed for complexes 1–3. Due to its favorable profile, complex 4 was selected for further assays, in which it inhibited colony formation and the cell migration of TNBC cells in a dose-dependent manner. Furthermore, this compound induced cell death independently of caspases, decreasing the activity of caspase 8. Interestingly, complex 4 sensitized TBNC cells to doxorubicin and paclitaxel, possibly modulating the epithelial–mesenchymal transition mechanism, as evidenced by increased CDH1 expression. Conclusions: Results suggest the potential of complex 4 in sensitizing aggressive BC cells to chemotherapy, proving to be a promising alternative in cases of therapeutic failure.

1 February 2016 in Journal of Molecular Structure
Verified
Journal Article
Closed access
ETEder C. Tavares
Eder C. Tavares
MRMayura M.M. Rubinger
Mayura M.M. Rubinger
EFEclair V. Filho
Eclair V. Filho
MOMarcelo R.L. Oliveira
Marcelo R.L. Oliveira
DPDorila Piló-Veloso
Dorila Piló-Veloso
LZLaércio Zambolim
Laércio Zambolim